March-in campaign on Pfizer's prostate cancer med Xtandi gets congressional backing. Will it matter?

Three lawmakers have thrown their support behind a plan that could empower the National Institutes of Health (NIH) to supply cheaper versions of Pfizer and Astellas' prostate cancer drug Xtandi—but will the campaign spur actual change?